<DOC>
	<DOCNO>NCT01316055</DOCNO>
	<brief_summary>The steady-state pharmacokinetics Dalfampridine-ER ( extended release ) 7.5 mg ( milligram ) tablets healthy adult volunteer mild moderate renal impairment , examine group comparison .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Dalfampridine-ER 7.5 mg BID Healthy Volunteers Subjects With Mild Moderate Renal Impairment</brief_title>
	<detailed_description>Pharmacokinetics normal , mildly renally impaired , moderately renally impaired subject</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Either gender age 18 75 year Have body mass index ( BMI ) range 18.5 35.0 kg/m2 , inclusive Have adequate cognitive function understand sign IRB approve informed consent prior performance studyspecific procedure Be willing able comply trial requirement Fit one three 12subject group : normal renal function ( CrCl &gt; 80 mL/min ) , mild renal impairment ( CrCl 5180 mL/min ) , moderate renal impairment ( CrCl 3050 mL/min ) Have sufficient venous access permit blood sample collection Women childbearing potential must negative Î²HCG pregnancy test Screening Visit . Women either pregnant breastfeeding , woman childbearing potential ( i.e. , hysterectomy bilateral oophorectomy , least two year postmenopausal ) engage active heterosexual relation use follow birth control method : tubal ligation , implantable contraception device , oral , patch injectible contraceptive , double barrier method , sexual activity restrict vasectomized partner ; History seizure ( ) ; Unstable , acute , severe ( CrCl &lt; 30 mL/min ) renal failure ; Clinically significant abnormal finding physical examination , ECG , vital sign , medical history , clinical laboratory result screen ( abnormal renal value ) ; Any unstable cardiovascular , enterohepatic , respiratory , immunologic disorder disease may substantially affect pharmacokinetics DalfampridineER ; Known allergy pyridinecontaining substance , inactive ingredient DalfampridineER tablet ( colloidal silicon dioxide , hydroxypropyl methylcellulose , magnesium stearate , microcrystalline cellulose , polyethylene glycol , titanium dioxide ) ; Participation investigational drug trial 30 day prior Screening plan enroll investigational drug trial time study ; Any medical condition include psychiatric disease would interfere interpretation study result conduct study ; Subject start new medication ( prescription , vitamin , herbal medication , overthecounter medication ) , change exist medication within 30 day prior screen ; History drug alcohol abuse past 2 year , test positive drug abuse Screening ; Donation blood blood component within 30 day prior administration investigational drug . The Investigator instruct subject participate study donate blood blood component participation study four week completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>